


Xolair CSU - Home - MOP Image



Image



Xolair® (omalizumab)

More information

Great Britain (GB) Summary of Product Characteristics (SmPC) for the <u>75 mg pre-filled</u> syringe and <u>autoinjector pen</u>, <u>150 mg pre-filled syringe</u> and <u>autoinjector pen</u>, and <u>300 mg pre-filled syringe</u> and <u>autoinjector pen</u> for Xolair.

Great Britain (GB) Patient Information Leaflet (PIL) for the <u>75 mg pre-filled syringe</u> and <u>autoinjector pen</u>, <u>150 mg pre-filled syringe</u> and <u>autoinjector pen</u>, and <u>300 mg pre-filled syringe</u> and <u>autoinjector pen</u> for Xolair.

These links will take you to the electronic medicines compendium Great Britain (emc) website, which is a non-Novartis website.

Northern Ireland (NI) Summary of Product Characteristics (SmPC) for the <u>75 mg pre-filled</u> syringe and autoinjector pen, <u>150 mg pre-filled syringe and autoinjector pen</u>, and <u>300 mg pre-filled syringe and autoinjector pen</u> for Xolair.

Northern Ireland (NI) Patient Information Leaflet (PIL) for the <u>75 mg pre-filled syringe</u> and <u>150 mg pre-filled syringe</u> for Xolair.

These links will take you to the electronic medicines compendium Northern Ireland (emc) website, which is a non-Novartis website.



Patient resources		
Patient resources		
See more details		

Hide details

UK October 2024 FA-11221723
Reporting side-effects
If you get side-effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side-effects not listed in the information leaflet that comes in the pack. You can report side-effects via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard . By reporting side-effects you can help provide more information on the safety of your medication.
Source URL: https://www.pro.novartis.com/uk-en/public/medicines/dermatology/xolair